mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

doi:10.1017/ice.2021.399

. 2022 Mar;43(3):393-395.

doi: 10.1017/ice.2021.399. Epub 2021 Sep 6.

mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

Aaron J Tande^#¹, Benjamin D Pollock^#^{2

3}, Nilay D Shah⁴, Matthew Binnicker⁵, Elie F Berbari¹

Affiliations

¹ Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
² Department of Quality, Experience, and Affordability, Mayo Clinic, Rochester, Minnesota.
³ Division of Health Care Delivery Research, Robert D. and Patricia E, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
⁴ Delta Air Lines, Atlanta, Georgia.
⁵ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

^# Contributed equally.

PMID: 34486511
PMCID: PMC8723985
DOI: 10.1017/ice.2021.399

mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

Aaron J Tande et al. Infect Control Hosp Epidemiol. 2022 Mar.

. 2022 Mar;43(3):393-395.

doi: 10.1017/ice.2021.399. Epub 2021 Sep 6.

Authors

Aaron J Tande^#¹, Benjamin D Pollock^#^{2

3}, Nilay D Shah⁴, Matthew Binnicker⁵, Elie F Berbari¹

Affiliations

¹ Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
² Department of Quality, Experience, and Affordability, Mayo Clinic, Rochester, Minnesota.
³ Division of Health Care Delivery Research, Robert D. and Patricia E, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
⁴ Delta Air Lines, Atlanta, Georgia.
⁵ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

^# Contributed equally.

PMID: 34486511
PMCID: PMC8723985
DOI: 10.1017/ice.2021.399

No abstract available

PubMed Disclaimer

Cited by

Estimate of undetected severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in acute-care hospital settings using an individual-based microsimulation model.
Jones K, Hadley E, Preiss S, Lofgren ET, Rice DP, Stoner MCD, Rhea S, Adams JW. Jones K, et al. Infect Control Hosp Epidemiol. 2023 Jun;44(6):898-907. doi: 10.1017/ice.2022.174. Epub 2022 Sep 1. Infect Control Hosp Epidemiol. 2023. PMID: 36047313 Free PMC article.
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here.
Halperin DT, Hearst N, Hodgins S, Bailey RC, Klausner JD, Jackson H, Wamai RG, Ladapo JA, Over M, Baral S, Escandón K, Gandhi M. Halperin DT, et al. BMC Public Health. 2021 Nov 13;21(1):2084. doi: 10.1186/s12889-021-12082-z. BMC Public Health. 2021. PMID: 34774012 Free PMC article. Review.
Cost-Effectiveness of Universal Asymptomatic Preoperative SARS-CoV-2 Polymerase Chain Reaction Screening: A Cost-Utility Analysis.
Uno S, Goto R, Honda K, Uchida S, Uwamino Y, Namkoong H, Yoshifuji A, Mikita K, Takano Y, Matsumoto M, Kitagawa Y, Hasegawa N. Uno S, et al. Clin Infect Dis. 2024 Jan 25;78(1):57-64. doi: 10.1093/cid/ciad463. Clin Infect Dis. 2024. PMID: 37556365 Free PMC article.
The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis.
Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Schweizer ML, Diekema DJ, Tofaneto BM, Bariani LM, Auler MA, Salinas JL, Edmond MB, Pinho JRR, Rizzo LV. Marra AR, et al. Antimicrob Steward Healthc Epidemiol. 2022 Feb 14;2(1):e22. doi: 10.1017/ash.2021.261. eCollection 2022. Antimicrob Steward Healthc Epidemiol. 2022. PMID: 36310810 Free PMC article. Review.
Finding the off-ramp: Rethinking severe acute respiratory coronavirus virus 2 (SARS-CoV-2) preoperative screening.
Penney JA, Doron SI. Penney JA, et al. Infect Control Hosp Epidemiol. 2022 Jul;43(7):918-919. doi: 10.1017/ice.2022.2. Epub 2022 Jan 6. Infect Control Hosp Epidemiol. 2022. PMID: 34986925 Free PMC article. No abstract available.

References

1. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021. doi: 10.1093/cid/ciab361. - DOI - PMC - PubMed
1. Abu-Raddad LJ, Chemaitelly H, Butt AA, National study group for C-V. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187–189. - PMC - PubMed
1. Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis 2021. doi: 10.1093/cid/ciab229. - DOI - PMC - PubMed
1. Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 2021;325:2500–2502. - PMC - PubMed
1. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–1829. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021. doi: 10.1093/cid/ciab361. - DOI - PMC - PubMed

[2] Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021. doi: 10.1093/cid/ciab361. - DOI - PMC - PubMed

[3] Abu-Raddad LJ, Chemaitelly H, Butt AA, National study group for C-V. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187–189. - PMC - PubMed

[4] Abu-Raddad LJ, Chemaitelly H, Butt AA, National study group for C-V. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187–189. - PMC - PubMed

[5] Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis 2021. doi: 10.1093/cid/ciab229. - DOI - PMC - PubMed

[6] Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis 2021. doi: 10.1093/cid/ciab229. - DOI - PMC - PubMed

[7] Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 2021;325:2500–2502. - PMC - PubMed

[8] Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 2021;325:2500–2502. - PMC - PubMed

[9] Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–1829. - PMC - PubMed

[10] Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–1829. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

Affiliations

mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous